The UK and US have finalized a landmark trade agreement that will maintain zero duties on British medicine exports being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase funding on medicines through the NHS. This commitment ensures that import taxes on these crucial products will remain at nothing for a period of the next three years.
This deal comes after previous threats to dramatically increase import taxes on branded pharmaceutical imports, with potential rates mentioned up to double the cost.
"This agreement between the UK reinforces the worldwide climate for new treatments and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," an announcement said.
Economic Impact
Medicines represent one of the Britain's largest export categories to the America, which is clearly the primary destination for leading UK drugmakers.
Trade data indicate that in the year to the end of the third quarter, the UK exported medicines worth billions to the US. This figure accounted for 17.4% of all goods exports in that span.
"This agreement protects jobs, boosts investment and facilitates the UK to become a international leader for biotech and pharma," a government official remarked.
Detailed UK Commitments
The pact involves several key commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to control costs will be limited at fifteen percent. Last year, rebates were more than twenty percent.
Industry Background
The pact takes place against a long-running row between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
The disagreement were intensified by claims that US customers were paying a premium for the same drugs than patients in the Britain and the EU.
Recently, several major drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been directed toward American operations.
One official stated that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had shrunk as a share of its total funding over the past decade.
